$8.76
6.18% today
Nasdaq, Aug 12, 07:10 pm CET
ISIN
CA31447P1009
Symbol
FENC

Fennec Pharmaceuticals Inc. Stock price

$8.25
-0.53 6.04% 1M
+1.75 26.92% 6M
+1.93 30.54% YTD
+2.00 32.00% 1Y
+1.21 17.10% 3Y
+1.59 23.87% 5Y
+5.93 255.60% 10Y
-54.16 86.78% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.08 0.96%
ISIN
CA31447P1009
Symbol
FENC
Industry

Key metrics

Basic
Market capitalization
$227.9m
Enterprise Value
$223.2m
Net debt
positive
Cash
$22.7m
Shares outstanding
28.0m
Valuation (TTM | estimate)
P/E
negative | 48.1
P/S
7.4 | 4.8
EV/Sales
7.2 | 4.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-13.0%
Return on Equity
7.5%
ROCE
-31.8%
ROIC
-
Debt/Equity
-3.1
Financials (TTM | estimate)
Revenue
$30.9m | $47.9m
EBITDA
- | $17.6m
EBIT
$-12.0m | $6.2m
Net Income
$-14.5m | $4.8m
Free Cash Flow
$-16.3m
Growth (TTM | estimate)
Revenue
-31.3% | 0.8%
EBITDA
- | -
EBIT
-284.5% | 140.1%
Net Income
-580.1% | 1,190.9%
Free Cash Flow
-159.5%
Margin (TTM | estimate)
Gross
90.3%
EBITDA
- | 36.8%
EBIT
-38.8%
Net
-46.8% | 10.0%
Free Cash Flow
-52.8%
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
6.8%
Employees
32
Rev per Employee
$1.5m
Show more

Is Fennec Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy
91%
Hold
9%

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
31% 31%
100%
- Direct Costs 3.01 3.01
75% 75%
10%
28 28
35% 35%
90%
- Selling and Administrative Expenses 40 40
9% 9%
130%
- Research and Development Expense 0.40 0.40
567% 567%
1%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
285% 285%
-39%
Net Profit -14 -14
580% 580%
-47%

In millions USD.

Don't miss a Thing! We will send you all news about Fennec Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fennec Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
one day ago
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day...
Neutral
GlobeNewsWire
2 months ago
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025.
Neutral
Seeking Alpha
3 months ago
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning,...
More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office Canada
CEO Jeffrey Hackman
Employees 32
Founded 1996
Website fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today